Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Amer Sports Inc (AS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Amer Sports Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $223.11 (market cap $29.60B), while Amer Sports Inc trades at $33.44 (market cap $19.69B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and Amer Sports Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | AS | |
|---|---|---|
Market Cap | $29.60B | $19.69B |
Sector | Health | Technology |
52-Week High | $491.22 | $41.96 |
52-Week Low | $205.48 | $29.54 |
Enterprise Value | $27.56B | $20.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $216.98, down 1.01% with bearish technical signals. The company shows strong revenue growth from $1.0B in 2022 to $3.7B in 2025, turning profitable with $314M net income. However, recent Q2 2026 earnings missed expectations, and multiple law firms are investigating potential securities fraud. Analyst consensus remains bullish with a $370.07 price target despite recent volatility.
The stock faces near-term pressure from legal investigations and earnings volatility, but strong fundamentals and analyst support suggest long-term potential. Key risks include legal outcomes and execution on growth targets, while the 71% upside to consensus target offers opportunity if the company can maintain its revenue trajectory.
Amer Sports (AS) trades at $33.67, down 6.91% over 24 hours, with a bearish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $0.38 and revenue growth of 32% year-over-year, and raised full-year guidance. Key financials show a net income margin of 6.5% and positive cash flow from operations of $729.8 million in 2025.
The outlook is supported by analyst consensus with 12 buy ratings and a $58.67 price target, but risks include high valuation multiples like a P/E of 42.3 and competitive pressures in the sports apparel sector. Near-term focus is on Q2 2026 earnings due August 18, 2026, which could drive volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Amer Sports Inc
Amer Sports is a global group of iconic sports and outdoor brands, including Arc'teryx, Salomon, Wilson, and Atomic. It designs and manufactures high-quality equipment, apparel, and footwear for athletes worldwide.
Read more on AS →
